# Tacalyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tacalyx

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.tacalyx.com
- Total disclosed funding: $28M
- Latest round: Series A (Mar 5, 2026)
- Investors on record: 8

## About

Based in Germany, Tacalyx GmbH, a.k.a. Tacalyx developing novel antibody-based cancer therapies by targeting tumour-associated carbohydrate antigens (TACAs), an underexplored class of highly specific tumour cell surface markers. Based in Berlin, Germany, founded in 2019 by Co-founder and CSO Peter Sondermann, Tacalyx GmbH, a.k.a. Tacalyx is a biotechnology company that develops therapeutics to target cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors. In April 2026, Tacalyx GmbH raised EUR 11 million in series A funding from Boehringer Ingelheim Venture Fund, Kurma Partners, High-Tech Gründerfonds, Eurazeo, Creathor Ventures, and Thuja Capital. The round was part of larger EUR 25 million in series A funding. Jean Engela is serving the role of CEO. Tacalyx develops anticancer therapeutics that target tumor-associated carbohydrate antigens (TACAs). These antigens, typically found in embryonic development and highly expressed in tumors, serve as targets for novel immunotherapies. Tacalyx's pipeline includes various treatment modalities, such as antibody-drug conjugates and T cell engagers, aimed at different TACAs across multiple solid tumors. Tacalyx GmbH is an early-stage biotech company that does not generate significant commercial revenue. The company is primarily funded through venture capital and research financing, while focusing on developing oncology drug candidates. Future revenue is expected from licensing deals, strategic partnerships, or commercialization milestones tied to its antibody-based cancer therapies. The company plans to use the April 2026 funding to to advance its lead TACA-targeting ADC programme, TCX-201, through preclinical development and to progress its broader oncology pipeline toward clinical development.

## Funding rounds

- Series A, Mar 5, 2026, $13M — Creathor Ventures, Max Planck Foundation, Boehringer Ingelheim Venture, Kurma Partners, Thuja Capital, High-Tech Gruenderfonds
- Series A, May 15, 2024, $7.5M — Idinvest Partners, Creathor Ventures, Max Planck Foundation, Boehringer Ingelheim Venture, Kurma Partners, Thuja Capital, High-Tech Gruenderfonds, Coparion
- Series A, Jul 2, 2019, $7.8M — Idinvest Partners, Creathor Ventures, Boehringer Ingelheim Venture, Kurma Partners, High-Tech Gruenderfonds, Coparion

## Investors

- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series A
- Creathor Ventures (https://capitalatlas.ai/funds/creathor-ventures) — Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series A
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A
- Coparion (https://capitalatlas.ai/funds/coparion) — Series A
- Max Planck Foundation — Series A
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A